Dermatomyositis: management
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Dermatomyositis: management. Anti MDA5, Anti Mi-2, Anti NXP2, Anti SAE, Anti TIF1. Fully referenced neurology checklist.
Autoantibody tests
- Anti MDA5
- Anti Mi-2
- Anti NXP2
- Anti SAE
- Anti TIF1
- Also see Neurochecklists: “Inflammatory myopathy antibodies”
Muscle enzymes
Locked: subscribe to see this section.
Electromyogram (EMG): features
Locked: subscribe to see this section.
Muscle biopsy
Locked: subscribe to see this section.
Magnetic resonance imaging (MRI) muscle
Locked: subscribe to see this section.
Other investigations
Locked: subscribe to see this section.
Treatment
Locked: subscribe to see this section.
References
- Dalakas MC. Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. Ther Adv Neurol Disord 2008; 1:157-166.
- Mammen AL. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184:134-153.
- Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. JNNP 2009; 80:1060-1068.
- Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol 2018; 17:816-828.
- Susac JO, Garcia-Mullin R, Glaser JS. Ophthalmoplegia in dermatomyositis. Neurology 1973; 23:305-310.
- And 14 more. Subscribe to see the full list
